Investor Presentation: First Nine Months of 2020
63
Investor presentation First nine months of 2020
Solid commercial execution is driving 13% NorditropinⓇ sales
growth in the first nine months of 2020
Historic reported sales
for NorditropinⓇ
DKK
40%
billion
8% 14% -22% 7%
2% 13%
9
30%
6
3
20%
10%
NorditropinⓇ value leadership maintained
despite increasing competition
35.3%
0
0%
2015 2016 2017 2018 2019 9M
2020
Aug
2015
Novo Nordisk
⚫Pfizer
Aug
2020
Norditropin Growth at CER
Eli Lilly
Roche
Merck Kgaa
-Other
Sandoz
Note: Company reported sales; CER: Constant exchange rates
Note: IQVIA, MAT value DKK, Aug 2020
Novo NordiskⓇ
Continue frequent launches with new
indications and device upgrades
Device portfolio
norditropin
simpleXx
somatropin (rDNA origin) injection
norditropin
flexpro
somatropin (rDNA origin) injection
norditropin
nordilet
somatropin (rDNA origin) injection
norditropin
nordiflex®
somatropin (rDNA origin) injection
norditropin
somatropin (rDNA origin) injection
Noonan syndrome,
EU device upgrades
Current
launches
Towards
2022
16
+
30View entire presentation